Royalty Report: Drugs, Vaccine, Viral Infection – Collection: 364018


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Vaccine
  • Viral Infection
  • Medical
  • Diagnostic
  • Test/Monitoring
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 364018

License Grant
University hereby grants to Licensee and Licensee hereby accepts an exclusive license, subject to any rights of the government in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights and a nonexclusive license to the know-how developed as of Effective Date by Natasa Strbo and Laura Romero (the Inventors) that is not encumbered by any third party rights, which is necessary to practice the Patent Rights to research, develop, make, have made, use, commercialize, market, promote, distribute, export, sell, offer to sell , or otherwise offer to dispose of Products in the Field of Use in the Territory and import the Product(s) and to practice the Process(es) described and/or claimed in the Patent Rights.
License Property
Technologies/Intellectual Property Provisional patent application entitled 'VECTORS AND VACCINE CELLS FOR IMMUNITY AGAINST ZIKA VIRUS' and filed 11-0ct-2016 with the US Patent and Trademark Office and assigned application number 62/406,506.
Field of Use
Field of Use shall mean GP96-lg-based vaccines against Zika Virus.

Zika Virus is a virus that is spread by mosquitoes.

IPSCIO Record ID: 381834

License Grant
University grants to the Australian Licensee, and any of its affiliates (i) an exclusive license under the patents to discover, develop, manufacture, have made, use, sell, offer to sell, have sold, import, export, distribute, rent or lease Products in the Field and throughout the world (ii) a non-exclusive license to use Technical Information to discover, develop, manufacture, have made, use, sell, offer to sell, have sold, import, export, distribute, rent or lease Products in the Field and throughout the world, and (iii) an exclusive license to use Materials to discover, develop, manufacture, have made, use, sell, offer to sell, have sold, import, export, distribute, rent or lease Products in the Field and throughout the world.

University further granted Licensee the right to grant sublicenses. All rights granted to Licensee were reserved to University.

License Property
Product is for ArboViroPlex rRT-PCR Test, a multiplex assay that can simultaneously test for for Zika virus, all dengue virus serotypes, Chikungunya virus and West Nile virus.

Patent 62/431,550 'Differential Molecular Diagnostic Assay for Zika'

Field of Use
Field of use is for the testing of various viruses, including for Zika virus, all dengue virus serotypes, Chikungunya virus and West Nile virus.

The research program is  in the field of CII-ArboViroPlex rRT-PCR Test, a multiplex assay that can simultaneously test, detect and differentiate the Zika virus, all Dengue virus serotypes, Chikungunya virus and West Nile virus.  The key advantage of this diagnostic kit is the ability to detect and differentiate almost instantaneously the four viruses.

IPSCIO Record ID: 248395

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive worldwide license to use the Intellectual Property to develop, make, or have made, use, keep, sell, offer to sell, import and export Licensed Products.
License Property
The Intellectual Property shall mean the Patents and knowhow, technical information and materials, including but not limited to cell lines, owned by the Licensor necessary or useful to develop, manufacture, have manufactured, import use, keep, sell and offer to sell the Plague Antigen and/or Vaccine.

Licensed Product shall mean a Plague Antigen, and/or a Vaccine including but not limited to a Plague Vaccine Dose, the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the license granted under this Agreement, constitute an infringement of the Patents or that uses other Intellectual Property.

Plague Antigen shall mean individually each of the F1 antigen and V antigen of Yesinnia Pestis.

Plague Vaccine Dose shall mean the quantity of Vaccine given to an individual in a single dose.

Patents are for Plague Vaccines and Vaccine Compositions.

Field of Use
The field of use for any UK Government purpose or otherwise to the extent customary pursuant to standard UK Ministry of Defense contracting procedures.

IPSCIO Record ID: 277105

License Grant
For outside the licensed field, Licensor grants a worldwide, non-exclusive, and sublicenseable right and license to practice Licensors rights in Joint Collaboration Patent Rights to make, have made, import, promote, market, distribute or sell Licensee Products outside the Licensed Field.

This agreement contains both exclusive and non-exclusive grants between the parties.

License Property
The Patent Rights and Know-How are pertaining to the PADRE® Technology.

Licensed Product shall mean a therapeutic or prophylactic vaccine the manufacture. use or sale of which, but for any license granted to Licensee herein, would infringe a Valid Claim of one or more Licensor Patent Rights or one or more Collaboration Patent Rights, or was developed or manufactured using Licensor Know-How.

PADRE® Technology shall mean a family of immunostimulatory molecules which when combined with cytotoxic T cell epitopes increase the magnitude and duration of the immune response.

Field of Use
Licensed Field shall mean the research, development and commercialization of Licensed Products for treating or preventing diseases associated with the following viruses HPV. HBV and HCV.  HBV shall mean Hepatitis B Virus.  HCV shall mean Hepatitis C Virus.  HPV shall mean Human Papilloma Virus.  First HPV Indication shall mean treatment or prevention of cervical dysplasias and neoplasia.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.